Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies

SIMPLE SUMMARY: Genetic rearrangements of the ROS1 gene account for up to 2% of NSCLC patients who sometimes develop brain metastasis, resulting in poor prognosis. This review discusses the tyrosine kinase inhibitor crizotinib plus updates and preliminary results with the newer generation of tyrosin...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Angelo, Alberto, Sobhani, Navid, Chapman, Robert, Bagby, Stefan, Bortoletti, Carlotta, Traversini, Mirko, Ferrari, Katia, Voltolini, Luca, Darlow, Jacob, Roviello, Giandomenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694780/
https://www.ncbi.nlm.nih.gov/pubmed/33172113
http://dx.doi.org/10.3390/cancers12113293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694780/
https://www.ncbi.nlm.nih.gov/pubmed/33172113
http://dx.doi.org/10.3390/cancers12113293

Ejemplares similares